ClinicalTrials.gg
RecruitingNCT07470762Updated Apr 13, 2026

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

A Phase 1/2 interventional study of HS-10542 and HS-10542 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Planned enrollment
18th of 47
50 · median 40
Started
2026
with 6 others
Phase 1/2
Only one
of the 51
Primary completion
2027-05
later than 16 of 28 live
Registered
44th of 51
by date

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 18th largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 16 of the 28 other live ones, and was the 44th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This was a phase 1b/2,open label, multi-center study to assess efficacy and safety of HS-10542 in adulte patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis.

Read the detailed description

HS-10542 is a novel oral small molecular weight compound that inhibits factor B (FB) of the alternative pathway (AP). Blockade of the AP with oral HS-10542 has the potential to prevent both intra - and extravascular hemolysis. This study consists of a dose exporation(Ph1b) and a dose expansion(Ph 2):

Phase Ib:In participants with paroxysmal nocturnal hemoglobinuria (PNH), two dose levels of HS-10542 will be explored (low dose; high dose randomized 1:1), stratified by whether the patient is currently receiving C5 complement inhibitor therapy. Based on an integrated assessment of interim data on the safety, efficacy, and PK/PD profile of HS-10542 in the target population, the recommended Phase II dose (RP2D) will be determined.

Phase II:Based on the safe and effective dose identified in Phase Ib, the efficacy and safety of HS-10542 will be evaluated in participants with PNH who have an inadequate response to C5 complement inhibitor therapy.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • HS-10542
  • paroxysmal nocturnal hemoglobinuria(PNH)
  • CFB
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged more than or equal to (≥) 18 years, and less than (≤) 75 years.
  2. It was confirmed to be PNH during screening, and the clone size of red blood cells or/and granulocytes or/and monocytes was detected by flow cytopy ≥10%
  3. Stable use of C5 complement inhibitor ikuzumab/covalimab for the first 6 months of random treatment
  4. Have at least one blood transfusion record within the last 4 months, or sustain a level below 100g/L the last 4 months prior to screening.
  5. The average hemoglobin level from two tests conducted by the laboratory at the time of screening is less than 100 g/L, or hemoglobin level \<100g/L before transfusion.
  6. LDH > 1.5 x (ULN) at the time of screening
  7. Inoccution of Neisseris meningitis and Streptococcus pneumoniae vaccine at least 2 weeks before the first administration of HS-10542;
  8. if HS-10542 treatment must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination.
  9. Male and female subjects with fertility must agree to adopt efficient measures with their partners within 60/120 days from the signing of the form to the last administration,
  10. Male subjects who are infertile (such as those who have undergone effective sterilization surgery) must take additional efficient contraceptive measures when it is uncertain whether they have sperm,

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected hereditary or acquired complement deficiency
  2. Currently active primary or secondary immunodeficiency
  3. History of infection with pod bacteria (such as Neisseris meningitis, Streptococcus pneumoniae, etc.)
  4. Patients with laboratory evidence of bone marrow failure (reticulocytes \<100x109/L; \<30x109/L; neutrophils \<0.5x109/L);
  5. Presence of a bone marrow failure disorder (e.g., aplastic anemia, myelodysplastic syndrome, myelofibrosis)
  6. Presence of active anemia unrelated to PNH, such as renal anemia or anemia due to blood loss.
  7. There is or is suspected of systemic active bacteria, virus or fungal infection 2 weeks before the first administration of HS-10542 (according to the researcher's judgment)
  8. During screening, there are advanced heart disease (such as level IV),
  9. unstable thrombosis events that may exist for other causes,
  10. Abnormal : The absolute value of (QT interval corrected by Fridericia 's formula > 450 msec for males and > 470 msec for females; or other abnormalities as judged by the investigator.
  11. Major surgery within 3 months prior to the first dose. *Note: See Appendix for definitions of Grade 3/4 surgeries.
  12. Known active infection requiring systemic therapy
  13. Diagnosed malignant tumors in the past 5 years
  14. Those who have a history of splenectomy or History of bone marrow/hematopoietic stem cells or solid organ transplantation
  15. Severe or poorly controlled hypertension
  16. poorly controlled diabetes
  17. Those who are suspected of being allergic to experimental drugs or any ingredient in experimental drugs
  18. Use any of the following drugs, unless there is a stable treatment plan before screening: a) erythropoietin (ESA), hypoxic-inducing factor proaminoyl hydroxylase inhibitor (HIF-PHI) or for at least 8 weeks b) Systemic use of (≤15 mg/day Prednisone or equivalent doses of glucocorticoids) at least 4 weeks c) Vitamin K antagonists (such as warfarin) have a stable international standardized ratio () at least 4 weeks d) Low molecular weight heparin, oral anticoagulants such as aspirin, rvaroxaban, apifloxaban, etc. at least 4 weeks e) Iron supplements , vitamin B12, folic acid or androgen for at least 4 weeks
  19. Except for C5 complement inhibitors (including but not limited to ecucizumab and covalizumab), the situation of participating in other clinical trials or using other study drugs or approved therapies for experimental use before screening, and the trial drug is still within 5 half-lives or 2 weeks
  20. Participants who have previously received B-factor inhibitor treatment, with a treatment duration of no more than one week and having stopped taking the drug for more than five half-lives before screening, may not be excluded
  21. During screening, there are serious concurrent diseases, such as severe kidney disease (such as \<30 mL/min/1.73 m2, dialysis),
  22. /ALP>3×,
  23. Screening positive blood pregnancy test and breastfeeding women at the time of the visit,
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ph1b: HS-10542 two dose ;Ph2: RP2D

    Phase Ib:two dose levels of HS-10542 will be explored (low dose; high dose, randomized 1:1) Phase II: Based on the safe and effective dose identified in Phase Ib, the efficacy and safety of HS-10542 will be evaluated in participants with PNH who have an inadequate response to C5 complement inhibitor therapy

    Drug: HS-10542

Interventions

  • HS-10542 low dose,QD

  • HS-10542 high dose, QD

  • Orally QD ,The recommended dose from Ph1b

06

What researchers measure

Primary outcomes

  1. Phase 1b: Incidence and severity of adverse events

    Time frame: 12 weeks

  2. Phase 2: In the absence of red blood cell infusion the proportion of subjects with at least 3 times of ≥120 g/L of hemoglobin level measured 4 times between weeks 18 and 24

    Time frame: From the 18th to the 24th week

Secondary outcomes

  1. Phase 1b: In the absence of red blood cell infusion the proportion of subjects of ≥120 g/L of hemoglobin level between weeks 3 and 12

    Time frame: From the 3th to the 12th week

  2. Phase 1b: the Proportion of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 20g/L in the Absence of Red Blood Cell Transfusions

    Time frame: hemoglobin between Day 15 and Day 84 and absence of transfusions

  3. Phase 1b: The proportion of subjects who did not receive red blood cell infusion from week 3 to week 12

    Time frame: From the 3th to the 12th week

  4. Phase 1b: Change in LDH level from baseline

    Time frame: 12 weeks

  5. Ph1b:change from baseline in hemoglobin concentration

    Time frame: 12 weeks

  6. Phase 1b: Change From Baseline in Hgb.LDH.free-Hgb. haptoglobin and ferritin

    Time frame: by week 2 and week 4

  7. Phase 1b: The number of red blood cell units transfused by the participants who received blood transfusions

    Time frame: 12 weeks

  8. Phase 1b: The average change of the score of Chronic Disease Treatment Function Assessment (FACIT) compared to the baseline

    The FACIT-F is a 13 -item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a 4-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.

    Time frame: Baseline and week 2, week 4, week 8, week 12

  9. Phase 1b: The incidence of breakthrough hemolysis(BTH)from Week 1 to week 12

    Time frame: From the 1th to the 12th week

  10. Phase 1b: The incidence of Major Adverse Vascular Events(MAVEs) from Week 1 to week 12

    MAVEs are recorded on the AE page/. MAVEs include but are not limited to the following conditions:Acute peripheral vascular occlusion; Gangrene, amputation (non-traumatic, non-diabetic participants); Transient ischemic attack; Cerebral artery/vein occlusion/cerebrovascular accident; Hepatic/portal vein thrombosis (Budd-Chiari syndrome); Mesenteric/visceral artery or vein thrombosis; Unstable angina; Myocardial infarction; Pulmonary embolism; Renal artery/vein thrombosis; Thrombophlebitis/deep vein thrombosis.

    Time frame: From the 1th to the 12th week

  11. Phase 2: the Proportion of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 20 g/L in the Absence of Red Blood Cell Transfusions

    Time frame: From the 18th to the 24th week

  12. Phase 2: The proportion of subjects who did not receive red blood cell infusion from week 3 to week 24

    Time frame: From the 3th to the 24th week

  13. Phase 2: the average change of Hemoglobin compared to the baseline

    Time frame: From the 18th to the 24th week

  14. Phase 2: the average change of Ret compared to the baseline

    Time frame: From the 18th to the 24th week

  15. Phase 2: the average change of LDH compared to the baseline

    Time frame: From the 18th to the 24th week

  16. Phase 2: Chronic Disease Treatment Function Assessment (FACIT) from weeks 18 to 24- the average change of the score compared to the baseline

    The FACIT-F is a 13 -item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a 4-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.

    Time frame: From the 18h to the 24th week

  17. Phase 2: Incidence and severity of adverse events

    Time frame: From the 1th to the 24th week

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Mar 13, 2026
StartActual
Feb 14, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Jul 31, 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07470762
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Feb 14, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Yan Hong Tong
Contact
hongyantong@aliyun.com
13958122357

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10542

Start the discussion